CL2019002218A1 - Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. - Google Patents
Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.Info
- Publication number
- CL2019002218A1 CL2019002218A1 CL2019002218A CL2019002218A CL2019002218A1 CL 2019002218 A1 CL2019002218 A1 CL 2019002218A1 CL 2019002218 A CL2019002218 A CL 2019002218A CL 2019002218 A CL2019002218 A CL 2019002218A CL 2019002218 A1 CL2019002218 A1 CL 2019002218A1
- Authority
- CL
- Chile
- Prior art keywords
- treat
- risk
- reduce
- cardiovascular disease
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MÉTODO PARA TRATAR O REDUCIR EL RIESGO DE ENFERMEDAD CARDIOVASCULAR QUE COMPRENDE ADMINISTRAR ETC-1002, EZETIMIBE Y UNA ESTATINA; FORMULACIÓN FARMACÉUTICA QUE COMPRENDE A ETC-1002, EZETIMIBE, UNA ESTATINA Y EXCIPIENTES; Y KIT QUE COMPRENDE A LA COMPOSICIÓN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762456571P | 2017-02-08 | 2017-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002218A1 true CL2019002218A1 (es) | 2020-02-21 |
Family
ID=63107115
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002218A CL2019002218A1 (es) | 2017-02-08 | 2019-08-06 | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
CL2021002447A CL2021002447A1 (es) | 2017-02-08 | 2021-09-21 | (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002447A CL2021002447A1 (es) | 2017-02-08 | 2021-09-21 | (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210361618A1 (es) |
EP (1) | EP3579827A4 (es) |
JP (2) | JP2020506241A (es) |
CN (1) | CN110536684A (es) |
BR (1) | BR112019016307A2 (es) |
CL (2) | CL2019002218A1 (es) |
IL (1) | IL268502A (es) |
MX (1) | MX2019009418A (es) |
WO (1) | WO2018148417A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102370582B1 (ko) | 2015-03-13 | 2022-03-04 | 에스페리온 테라피유틱스 인코포레이티드 | Etc1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법 |
JP2020506241A (ja) | 2017-02-08 | 2020-02-27 | エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. | トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法 |
JP2021534208A (ja) * | 2018-08-24 | 2021-12-09 | エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
EP3844168A4 (en) * | 2018-08-27 | 2022-05-18 | Esperion Therapeutics, Inc. | COMBINATION DRUG PREPARATIONS FOR THE TREATMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS |
WO2020213010A1 (en) | 2019-04-16 | 2020-10-22 | Celagenex Research (India) Pvt. Ltd. | Synergistic lipid controlling compositions |
US20230141635A1 (en) | 2019-06-21 | 2023-05-11 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
CN113133997B (zh) * | 2020-01-20 | 2024-02-09 | 深圳市长卿医学研究院 | 一种含小檗碱的药物组合物及其用途 |
CN113134086B (zh) * | 2020-01-20 | 2024-05-24 | 深圳市长卿医学研究院 | 一种降血脂的药物组合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006109170A2 (en) * | 2005-04-14 | 2006-10-19 | Esperion Therapeutics Inc. | Combination therapy for treatment of cardiovascular diseases and related conditions |
MX367352B (es) * | 2012-01-06 | 2019-08-16 | Gemphire Therapeutics Inc | Metodos para reducir el riesgo de padecer una enfermedad cardiovascular. |
US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
GB201318793D0 (en) * | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
KR102370582B1 (ko) * | 2015-03-13 | 2022-03-04 | 에스페리온 테라피유틱스 인코포레이티드 | Etc1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법 |
MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
JP2020506241A (ja) | 2017-02-08 | 2020-02-27 | エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. | トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法 |
-
2018
- 2018-02-08 JP JP2019563352A patent/JP2020506241A/ja active Pending
- 2018-02-08 EP EP18751030.0A patent/EP3579827A4/en active Pending
- 2018-02-08 BR BR112019016307-7A patent/BR112019016307A2/pt unknown
- 2018-02-08 MX MX2019009418A patent/MX2019009418A/es unknown
- 2018-02-08 WO PCT/US2018/017434 patent/WO2018148417A1/en unknown
- 2018-02-08 US US16/484,704 patent/US20210361618A1/en not_active Abandoned
- 2018-02-08 CN CN201880023209.6A patent/CN110536684A/zh active Pending
-
2019
- 2019-08-05 IL IL268502A patent/IL268502A/en unknown
- 2019-08-06 CL CL2019002218A patent/CL2019002218A1/es unknown
-
2021
- 2021-09-21 CL CL2021002447A patent/CL2021002447A1/es unknown
-
2023
- 2023-01-13 JP JP2023003431A patent/JP2023040237A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018148417A1 (en) | 2018-08-16 |
JP2020506241A (ja) | 2020-02-27 |
EP3579827A4 (en) | 2021-01-06 |
CN110536684A (zh) | 2019-12-03 |
CL2021002447A1 (es) | 2022-04-22 |
US20210361618A1 (en) | 2021-11-25 |
BR112019016307A2 (pt) | 2020-03-31 |
IL268502A (en) | 2019-09-26 |
MX2019009418A (es) | 2019-10-02 |
JP2023040237A (ja) | 2023-03-22 |
EP3579827A1 (en) | 2019-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
GT201700179A (es) | Formulaciones en polvo nasal para el tratamiento de hipoglicemia | |
CL2017002334A1 (es) | Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
CR20180080A (es) | Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
BR112021000279A8 (pt) | formulações de redução de tumor e métodos de uso das mesmas | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
BR112018074655A2 (pt) | formulação injetável de fosnetupitant e método de fabricação de uma formulação | |
CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
CL2020000586A1 (es) | Moduladores de la expresión de enac. | |
CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |